Roche, Fujirebio partner for new ovarian cancer test
MALVERN, Pa. Roche Diagnostics and Fujirebio have entered a license and supply agreement for a new test for ovarian cancer, the two companies announced on Tuesday, Dec. 16.
Under the agreement, Roche will develop an assay kit using Fujirebio’s HE4 test on its automated immunoassay analyzers.
Fujirebio developed the HE4 test for use in conjunction with its CA125 biomarker. The company said that the combination provides clinicians with a diagnostic tool more sensitive and specific than CA125 alone.
“This novel biomarker HE4 will allow our longstanding partner, Roche Diagnostics, to provide clinicians worldwide with a much-needed tool to better define a pelvic mass, enabling women at higher risk for cancer to see the right physician earlier,” Fujirebio president and CEO Paul Touhey said in a statement.
Gilead sues Teva over approval application for generic Truvada
NEW YORK Gilead Sciences has filed a lawsuit against Israeli generic drug maker Teva Pharmaceutical Industries and a subsidiary.
Gilead, which filed the suit Friday in a United States District Court in New York, alleged that Teva committed patent infringement when it filed an approval application with the Food and Drug Administration for a generic version of Truvada (emtricitabine), a drug for treating HIV.
Gilead has a license to manufacture and sell the drug from Emory University in Atlanta.
Take Care adds another clinic to its network in Miami/Fort Lauderdale area
CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened one new clinic in the Miami/South Fort Lauderdale area. The opening marks the 10th Take Care Clinic in the market.
The company currently operates 313 clinics in 18 states.